[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2892 Introduced in House (IH)]







106th CONGRESS
  1st Session
                                H. R. 2892

  To amend title XVIII of the Social Security Act to expand Medicare 
             coverage of certain self-injected biologicals.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 21, 1999

Ms. Dunn (for herself, Mr. Inslee, Mr. Metcalf, Mr. Baird, Mr. Hastings 
of Washington, Mr. Nethercutt, Mr. Dicks, Mr. McDermott, and Mr. Smith 
of Washington) introduced the following bill; which was referred to the 
  Committee on Commerce, and in addition to the Committee on Ways and 
 Means, for a period to be subsequently determined by the Speaker, in 
   each case for consideration of such provisions as fall within the 
                jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
  To amend title XVIII of the Social Security Act to expand Medicare 
             coverage of certain self-injected biologicals.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Access to Innovation for Medicare 
Patients Act of 1999''.

SEC. 2. MEDICARE COVERAGE OF SELF-INJECTED BIOLOGICALS.

    (a) Coverage.--
            (1) In general.--Section 1861(s)(2) of the Social Security 
        Act (42 U.S.C. 1395x(s)(2)) is amended--
                    (A) by striking ``and'' at the end of subparagraph 
                (S);
                    (B) by striking the period at the end of 
                subparagraph (T) and inserting ``; and''; and
                    (C) by inserting after subparagraph (T) the 
                following new subparagraph:
            ``(U) a self-injected biological (which is approved by the 
        Food and Drug Administration) that would be described in 
        subparagraph (A) or (B) but for the limitation on self-
        administration under such subparagraphs, and that is prescribed 
        for use in the treatment of the same disease or medical 
        condition in lieu of a drug or biological described in 
        subparagraph (A) or (B);''.
            (2) Conforming amendment.--Subparagraphs (A) and (B) of 
        such section are each amended by striking ``biologicals'' and 
        inserting ``biologicals (except as provided in subparagraph 
        (U))''.
    (b) Effective Date.--The amendments made by subsection (a) apply to 
biologicals furnished on or after January 1, 2000.
                                 <all>